The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy

We aimed to investigate the prognostic value of red cell distribution width (RDW) in metastatic renal cell carcinoma (mRCC) patients treated with targeted therapy, including sunitinib and pazopanib. A total of 104 mRCC patients were included. The Kaplan-Meier method was used to estimate overall surv...

Full description

Saved in:
Bibliographic Details
Published in:Nutrition and cancer 2021-11, Vol.73 (10), p.1957-1963
Main Authors: Aktepe, Oktay Halit, Guven, Deniz Can, Sahin, Taha Koray, Yildirim, Hasan Cagri, Celikten, Burcu, Yeter, Haci Hasan, Yuce, Deniz, Dizdar, Omer, Erman, Mustafa
Format: Article
Language:English
Subjects:
Cell survival
Confidence intervals
Erythrocytes
Kidney cancer
Metastases
Metastasis
Rank tests
Renal cell carcinoma
Statistical models
Survival
Therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to investigate the prognostic value of red cell distribution width (RDW) in metastatic renal cell carcinoma (mRCC) patients treated with targeted therapy, including sunitinib and pazopanib. A total of 104 mRCC patients were included. The Kaplan-Meier method was used to estimate overall survival (OS) and progression-free survival (PFS), and the long-rank test was used for comparison. Univariate and multivariate Cox proportional hazards models were used to determine the association between RDW and PFS and OS. The PFS and OS of all cohorts were 11.8 mo and 25.9 mo, respectively. Receiver operating characteristic analysis revealed that RDW level ≥15.4 was the optimal cutoff value for OS prediction with 73.53% sensitivity and 61.11% specificity (area under curve: 0.64, P = 0.012). RDW level ≥15.4 was found as an independent prognostic parameter for OS when adjusted for the number of covariates, including the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scoring system (hazard ratio: 1.125, 95% confidence interval: 1.024-2.235, P = 0.014). Our study revealed that high RDW level, a routinely and easily assessed marker, was significantly associated with worse survival outcomes in mRCC patients treated with targeted therapy.
ISSN:0163-5581
1532-7914
DOI:10.1080/01635581.2021.1871925